PCT Ltd (PCTL)

[MoonLambo]

Do a Google search. Like all things more trials are needed but it works well.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255448/

Methods

PubMed, Embase, ClinicalTrials.gov, ICTRP (WHO), Cochrane Library databases, and two pre-print servers (medRxiv.org and Research Square) were searched for clinical studies that evaluated the therapeutic role of HCQ on COVID-19 until 10 May 2020. The available studies were critically analyzed and the data were extracted.

Results

A total of 663 articles were screened and 12 clinical studies (seven peer-reviewed and published studies and five non-peer-reviewed studies from pre-print servers) with a total sample size of 3543 patients were included. Some of the clinical studies demonstrated good virological and clinical outcomes with HCQ alone or in combination with azithromycin in COVID-19 patients, although the studies had major methodological limitations. Some of the other studies showed negative results with HCQ therapy along with the risk of adverse reactions.

June 4: The Lancet retracted the study it published May 22 that claimed hydroxychloroquine was linked to higher mortality rates in COVID-19 patients. 
On the same day, The New England Journal of Medicine retracted a separate study showing that blood pressure medications were safe to take for COVID-19 patients. Both studies used data from analytics company Surgispher, which refused to share its raw data with study authors or a third-party auditor after questions about its accuracy arose. 
June 5: A U.K.-based, non-peer-reviewed study showed no significant difference in the death rate at 28 days between COVID-19 patients who received the drug and those who did not.
On the same day, Salt Lake City-based University of Utah terminated its faculty appointment of Amit Patel, MD, who co-authored the two medical papers on hydroxychloroquine that had been recently retracted by The Lancet and The New England Journal of Medicine.